[A20-114] Nusinersen (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V
Last updated 20.05.2021
Project no.:
A20-114
Commission:
Commission awarded on 02.12.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Patients with 5q spinal muscular atrophy (SMA)
Early onset of disease (infantile form, type 1): indication of major added benefit. Later onset of disease (type 2, type 3 and type 4): added benefit not proven. Pre-symptomatic patients: hint of non-quantifiable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G17-05 | Nusinersen (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V | Commission completed |
| A21-43 | Nusinersen (spinal muscular atrophy) - Addendum to Commission A20-114 | Commission completed |
Federal Joint Committee (G-BA)
2021.05.20 A G-BA decision was published.